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E-mail address: eric.so@kcl.ac.uk (C.W.E. So).Identiﬁcation of transcription factors as prevalent targets affected by recurring chromosomal trans-
locations has provided the ﬁrst hint for the importance of transcriptional deregulation in haemato-
logical malignancies. However, the actual molecular functions of these leukaemia-associated
transcription factors on gene expression remained largely unknown until the recent discovery of
their association with speciﬁc enzymatic activities that modify epigenetic codes (at DNA and/or his-
tone levels) of downstream transcriptional targets. Intriguingly, while only just about half of acute
leukaemia associates with recurring translocations, emerging evidence indicates that cryptic muta-
tions identiﬁed in the ‘‘normal-karyotype’’ leukaemia also frequently affect components of epige-
netic machinery. We will review these recent ﬁndings and discuss their implications in
understanding the biology of the disease and in development of effective cancer therapeutics.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Recurrent chromosomal translocations that result in the forma-
tion of chimaeric fusion proteins are pivotal for the initiation and
progression of human cancers, and in particular, in haematological
malignancy [1–3]. In human leukaemia, many of the oncogenic fu-
sion proteins encode transcription factors with aberrant transcrip-
tion activities leading to dysregulation of their critical target genes
and downstream transcriptional programmes that drive the onco-
genesis. Targeting leukaemic fusion protein has led to few but sig-
niﬁcant therapeutic achievements in the past few decades for the
treatment of human malignancy. In patients suffering from acute
promyelocytic leukaemia (APL), differentiation therapy using all
trans-retinoic acid (ATRA) and arsenic trioxide to induce terminal
differentiation and apoptosis of leukaemic cells harbouring
PML-RARa (promyelocytic leukaemia-retinoic acid receptor a) leu-
kaemic fusion has transformed it from a fatal to a highly curable
disease [4]. Similarly, the introduction of imatinib mesylate (Glee-
vec; STI571), a small molecule inhibitor for kinase activity of the
BCR-ABL fusion in chronic myeloid leukaemia (CML), has converted
a fatal cancer into a manageable chronic condition in patient [5].
However, the treatment for the majority of human leukaemias still
relies heavily on the conventional chemotherapy with associated
side effects and disease prognosis remain dismal for many sub-
types of haematological malignancies such as MLL leukaemia.
Hence, a better understanding of the underlying leukaemogeniccal Societies. Published by Elseviermechanisms is critical for invention of rational therapeutic ap-
proach for the eradication and/or control of these highly malignant
diseases. Emerging evidence indicates that an array of epigenetic
enzymes plays important roles in the leukaemic transformation,
and potentially represents a plethora of amendable targets for
therapeutic intervention. In this review, we will examine and dis-
cuss the implications of some of the recent discoveries that impor-
tant epigenetic machineries are hijacked or directly mutated in
human leukaemia.
2. Histone code: the writers and the readers
The role of epigenetic modiﬁcation, particularly DNA methyla-
tion, in the regulation of gene expression in normal and in cancer
cells has been extensively studied in the past few decades. Recent
advances in sequencing technology and the availability of highly
speciﬁc antibodies have greatly facilitated progress in the study
of the epigenetic landscape at both the nucleic acid and at histone
levels [6–8]. Different covalent post-translational histone modiﬁ-
cations of the histone octamers generates a myriad combination
of histone marks, which are collectively termed the ‘histone code’
[9,10]. These modiﬁcations are made by a large array of histone
‘‘writers’’ with distinct enzymatic activities. Histones can be meth-
ylated, ubiquitinated, phosphorylated, proline-isomerized, ADP-
ribosylated or modiﬁed by other means such as citrullination and
by proteolytic cleavage [10–13]. These histone marks can be read
and interpreted by other transcriptional regulators or epigenetic
modiﬁers, which possess motifs that are capable of speciﬁcally
interacting with the modiﬁed histones, e.g., bromodomainB.V. Open access under CC BY-NC-ND license.
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chromodomain bind methylated lysine [9,14,15]. These transcrip-
tional complexes are usually comprised of multi-modular compo-
nents that contain different copy numbers and combinations of
histone recognition motifs to facilitate their interaction with his-
tones [15].
3. Basic principles of the histone code
Histone modiﬁcation is a dynamic and reversible process regu-
lated by various histone-modifying enzymes that can cooperate
with or antagonise each other (Fig. 1). Of the complexity of covalent
histonemodiﬁcations, there are some basic principles regarding the
functional consequences of certain histone marks [11,16,17]. His-
tone lysine acetylation mediated by histone acetyltransferases
(HATs) is mostly associated with active transcription. The action of
these enzymes can be reversed by histone deacetylases (HDACs)
leading to histone hypoacetylation and is usually associated with
transcriptional suppression [18,19]. Methylation of histone tails is
much more complicated, as lysine residues can be mono-, di- or
tri-methylated, whereas arginine residues can be mono-, di-, sym-
metrical or asymmetrically methylated [11,20]. These methylated
lysine marks can be erased by the lysine speciﬁc demethylase 1
(LSD1) and Jumonji domain-containing family of histone lysine
demethylases (KDM) [21–23] (Figs. 1 and 2). Some histone methyl-
ation marks are strongly associated with transcriptional activation,
such as H3K4 trimethylation (H3K4me3)mediated by theMLL com-
plex or H3K79 dimethylation (H3K79me2) mediated by the Dot1
complex [24,25]. The H3K27 trimethylation (H3K27me3) mark,
mediated by Polycomb Repressor Complex 2 (PRC2), is critical for
transcriptional repression of genes, in particular those essential for
development and maintenance of cellular pluripotency [26]. H3K9
methylation is another histonemodiﬁcationusually associatedwith
transcriptional repression and the formation of constitutive and sta-
bly repressed heterochromatic regions, such as the inactivated X-
chromosome and in centromeric heterochromatin [27,28]. How-
ever, the demarcation of transcription status based on the histone
modiﬁcation is unclear in genes in the bivalent chromatin state
where bivalent genes are usually associated with the presence of
both active H3K4 trimethylation and the repressive H3K27 trime-
thylation marks in embryonic stem cells [26]. In this conﬁguration,
transcription activity is at a basal level, however, the bivalent gene
is at a poised statewhereby it can rapidly respond to developmental
cues and other stimuli [26]. Although it is not clear if the same prin-
ciple applies to somatic stem cells, studies usingmixed populations
of haematopoietic stem/progenitor cells show that many cell fateFig. 1. Schematic diagram illustrates a dynamic transcription regulation of critical de
Trithorax group (TrxG/MLL) complex. While it is generally believed a stepwise recruitm
simpliﬁed version for illustration of the core components of PRCs. Core enzymatic compo
histone 3 lysine 4; K27 histone 3 lysine 27; K119; histone 2A lysine 119, M, methylatiodecision genes are held in a transcriptionally poised bivalent state
until their commitment to differentiate [29].
4. Leukaemic fusions as aberrant transcriptional and epigenetic
regulators
Cytogenetic analyses and positional cloning have signiﬁcantly
contributed to the identiﬁcation of numerous chromosomal translo-
cations in human leukaemias and other cancers, which has now
been further facilitated by the technological advances inwhole gen-
ome sequencing [30–32]. Oncogenic chimaeric transcription factors
resulting from reciprocal translocations account for about half of
acute leukaemias [33]. Abnormal activity of the resulting leukaemic
chimaeric fusion protein can lead to the deregulation of the target
genes of their normal counterparts by altering the chromatin status
via aberrant recruitment of epigenetic regulators. We can broadly
classify chimaeric transcription factors into activating and repres-
sive leukaemic transcription factors based on their predominant
transcriptional activities on their direct downstream target genes,
which lead to distinct gene expression proﬁles [34,35] (Fig. 3).
Repressive leukaemic transcription factors transform haemato-
poietic cells through the recruitment of the co-repressor com-
plexes that result in the gain of repressive histone marks
accompanied by the loss of active marks. PML-RARa fusion is the
best-characterised repressive leukaemic fusion protein. It trans-
forms haematopoietic cells mostly though repression of its target
genes resulting in an accumulation of abnormal promyelocytes
[4]. Its aberrant transcription repressive function is mediated by:
(1) the acquisition of the ability to homo-oligomerise [36,37]; (2)
the recruitment of DNA binding cofactors such as RXRa [38,39];
and more importantly, (3) its speciﬁc association with co-repressor
complexes such as NCoR/HDAC, DNA methyltransferase DNMT3A
and PRC2 [40–42]. The RARa moiety of this oncogenic fusion pro-
tein is essential for its interaction with co-repressor complexes and
is a focal point for drug targeting. Although the key responsible
epigenetic enzymes remain unknown, the binding of therapeutic
drug ATRA to RARa releases the co-repressor complex and induces
terminal differentiation of the leukaemic cells by de-repression of
target genes [40,41]. In contrast, activating leukaemic transcription
factors, generally are involved in the aberrant recruitment of epige-
netic enzymes that deposit active histone marks and prevent the
accumulation of repressive marks. Mechanisms for the recruitment
of co-repressor complexes by repressive transcription factors have
been reviewed in the past, thus the current article will mainly fo-
cus on leukaemic fusion proteins, which predominantly activate
transcription [4,41,43].velopmental genes such as Hox by polycomb repressive complexes (PRC1/2) and
ent model of PRC2 and PRC1 by transcription factors, diagram shown above is a
nents of PRC1 (RING/BMI1), PRC 2 (EZH2) and MLL (MLL) comlexes are indicated. K4,
n; Ub, ubiquitination; KDM, lysine demethylase
Fig. 2. Dynamic regulation of histone methylation and ubiquitination. Purple and pink circles indicate methylation predominately associated with transcription activation
and repression respectively. Ubiquitination of lysine 119 of H2A regulated by PRC1 and PR-DUB [179]/ZRF [200] associates with transcription repression.
Fig. 3. Schematic diagram showing transcriptional deregulation by two distinctive types of leukaemic transcription factors. a. Activating leukaemic transcription factors
activate their critical target genes by recruiting histone-modifying enzymes that leave activation histone marks and prevent the accumulation of repressive marks. Histone
acetylation is mediated by histone acetyltransferases (HATs) such as CBP, p300 and MOZ. Increased active lysine methylation marks can be induced by lysine
methyltransferases (KMTs), e.g. DOT1L, NSD1 and MLL. Repressive lysine methylation marks may be removed by lysine demethylases (KDMs) such as JMJD3/UTX (H3K27)
and JMJD2 (H3K9) family members. Arginine methylation (H4R3) mediated by PRMT1 can also facilitate transcriptional activation. Activation complexes may also recruit TET
family proteins to remove the repressive promoter CpG methylation. b. Repressive leukaemic transcription factors recruit co-repressor complexes and other histone-
modifying enzymes to leave repressive histone marks and impede the deposition of active marks on their target genes. Histone deacetylases (HDACs) erase the active
acetylation marks thereby lead to promoter hypoacetylation and transcriptional repression. The JARID1 family and LSD1 family KDMs both contribute to the removal of the
active H3K4 methylation marks. H3K9 KMT (G9a, SETDB1) and PRC2 cause increased repressive H3K9 and H3K27 methylation marks, respectively. Gene silencing can be
stabilised by monoubiquitination of H2A by the PRC1 complex. Repressor complexes can also recruit DNA methyltransferases (DNMTs) to repress target gene expression by
inducing promoter CpG methylation.
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haematological malignancies
HOX, which have an essential role on the orchestration of the
embryonic development, are one of the most frequently dysregu-
lated targets in human leukaemias and other malignancies[44,45]. HOX genes such as HOXA9, HOXA10, HOXA11, HOXC13,
HOXD3 or HOXD13 have been found in translocations involving
NUP98 to generate chimaeric fusions in leukaemia patients [46].
Over-expression of HOX genes is frequently found in leukaemia pa-
tients, particularly in those chromosomal translocations, which in-
volve MLL and MOZ [34,47] (discussed in the next section). HOXA9
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acute myeloid leukaemia (AML) [48]. Knockdown of HOXA9 in hu-
man MLL leukaemia cells suppresses leukaemic cell survival
in vitro and reduces tumour burden in mouse models [49]. Fur-
thermore, over-expression of Hoxa9, together with its interaction
partner Meis1, is sufﬁcient to immortalise haematopoietic progen-
itor cells and induces acute myeloid leukaemia in vivo [50]. To-
gether these studies strongly support a pivotal role of HOX genes
in acute leukaemogenesis.
In embryonic stem cells (ESC), Hox genes are regulated and
maintained in the bivalent chromatin state by two antagonistic
transcription complexes, namely the activating Trithorax (e.g.,
MLL family protein) complexes and the silencing PRC1/2
[26,51,52]. MLL protein, which regulates Hox gene expression via
its H3K4 methyltransferase activity, is also required for normal
embryonic development and haematopoiesis [53,54]. The methyl-
ated H3K4 residue can be removed by the KDM1/LSD1 and KDM5/
JARID1 demethylase family [21–23] (Figs. 1 and 2). PRC2 comprises
of several core components that mediate gene silencing by trime-
thylation of H3K27 [55,56] (Fig. 1). The SET domain-containing
proteins, EZH1 and EZH2, are the catalytic subunits for H3K27 his-
tone methylation whereas SUZ12 and EED are essential for the
activation of EZH enzymatic activity [55–57]. PRC1, which com-
prises the E3 ubiquitin ligase RING1/RING1B, BMI1 and other com-
ponents, are essential for mono-ubiquitination of H2A and
maintenance of the repressive state [55,58]. PRCs are recruited to
their target genes through binding to speciﬁc DNA sequence ele-
ments known as the Polycomb Response Element [55,59]. Recently,
Jarid2, the founding member of Jumonji domain-containing pro-
tein, was found to be a component of the PRC2 and is involved in
ﬁne-tuning the activity of the complex [60–64]. The repressive
H3K27me3 mark on HOX genes can be speciﬁcally erased by the
histone lysine demethylases, JMJD3 and UTX, and provide an addi-
tional regulatory pathway to antagonise PRC-mediated gene
silencing [65–67] (Figs. 1 and 2). H3K27 demethylation can be fol-
lowed by CBP/p300-mediated histone acetylation to further rein-
force the transcription activation status [68]. In leukaemia, this
dynamic epigenetic regulation of HOX genes is altered by a number
of fusion proteins such as MLL, MOZ and NUP98 leukaemia fusions.
6. MLL gene rearrangement and HOX deregulation
The wild-type MLL protein, which has a C-terminal SET domain
that methylates H3K4 to activate transcription of target genes such
as HOX genes, forms a macromolecular nuclear transcription com-
plex with other core components (ASH2, WDR5, RBBP5, LEDGF,
MENIN, etc.) [69–72]. MLL located at chromosomal 11q23 is one
of the most frequently mutated genes in human leukaemia. MLLFig. 4. Schematic representation of the chromosomal aberrations of the MLL gene in h
terminal portions. Balanced translocations disrupt MLL at a breakpoint cluster region bet
MLL N-terminal domains such as the AT hook (AT), the subnuclear localization motif
bromodomain and the C-terminal SET domain are invariably deleted in the chimaeric fu
hook, SNL1/2 and CXXC are duplicated. Internal MLL deletion involving the PHD1 domacan be de-regulated in four different ways in leukaemia, namely
by gene ampliﬁcation, partial tandem duplication (PTD), internal
deletion or through fusion to a partner gene (Fig. 4). MLL-PTD
mutations are observed in approximately 8% of AML patients with
normal cytogenetics and in 25–54% of AML patients where trisomy
11 is the only identiﬁed abnormality [73,74]. MLL-PTD involves an
in-frame partial duplication of the exons encoding the DNA bind-
ing domain (encompassing the AT hook and CXXC domain) of
MLL. In the MLL-PTD knockin mouse model, MLL-PTD cells upreg-
ulate Hoxa9 expression with a concomitant increase in H3K4
methylation and H3 acetylation at the locus, suggesting a domi-
nant gain-of-function effect on transcription activation [75].
HOXA9 overexpression can also be detected in patients with the
11q23/MLL gene ampliﬁcation, which accounts for approximately
1% of AML and some myelodysplastic syndromes (MDS) patients
[76,77]. In contrast to MLL internal deletion, which can only be
found in rare cases of T-cell acute lymphoid leukaemia (T-ALL),
MLL fusion proteins, which account for 5–10% of adult acute leu-
kaemia, 25% of therapy related leukaemia, and around 80% of in-
fant leukaemia, are one of the best studied leukaemias with a
remarkable number of publications detailing their biochemical
mechanisms, mouse models and clinical data [78–82]. In MLL leu-
kaemia patients, the translocation usually involves only a single
copy of MLL and the wild-type MLL allele is presumably functional
in the leukaemic cells. This remaining wild-type MLL is required
for the H3K4 trimethylation of Hoxa9. MLL leukaemic fusion is un-
able to immortalise haematopoietic cells where the MLL gene has
been down-modulated by knockout or shRNA approaches [83].
MLL is a promiscuous gene that can fuse with over 50 different
partner genes of both nuclear and cytoplasmic proteins [80,84–86].
This results in the generation of chimaeric MLL proteins with gain
of transactivation functions provided by the fusion partners. The
translocation breakpoints of MLL usually cluster between the
exons encoding the CXXC-RD2 motif and the PHD ﬁngers (Fig. 4).
This leads to the retention of some essential motifs of MLL N-ter-
minus, such as the DNA-binding AT-hook motif, and the deletion
of MLL C-terminus which contains the PHD domain and SET do-
main, which speciﬁcally methylates H3K4 [87]. The position of
the breakpoint cluster region of MLL is critical for the oncogenic
activity of MLL fusion proteins. This was ﬁrst illustrated by the syn-
thetic inclusion of the third PHD ﬁnger motif (PHD3), which is
invariably absent from the MLL fusion proteins, and results in com-
promised transformation [88,89]. Structure-function studies of the
PHD3 with its adjacent bromodomain, revealed a critical functional
recruitment of cyclophilin 33 (CyP33) for the induction of a speciﬁc
conformational change in MLL by catalysing the cis-trans isomeri-
sation of proline in the linker between PHD and bromodomain of
MLL which is required for co-repressor complex recruitment [90].uman leukaemia. MLL protein is proteolytically processed into N-terminal and C-
ween exons encoding the CXXC motif and the ﬁrst PhD domain. After translocation,
s (SNL1 & SNL2) and the CXXC motifs are retained whereas the PHD ﬁngers, the
sion protein. In MLL partial tandem duplication, N-terminal domains including AT
in is also detected in some cases of leukaemia.
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in T-ALL suggests that this loss-of-function mutation could be leu-
kaemogenic [91]. Recruitment of epigenetic regulators mediated
by the MLL N-terminus has been recently reported by Muntean
et al., whereby they identiﬁed the recruitment of the polymerase
associated factor complex (PAFc) by the CXXC and RD2 motif of
MLL. PAFc plays a critical role in mediating H2B ubiquitination,
which has been shown to promote H3K4 and H3K79 methylation
for transcriptional activation [92,93]. Recruitment of the PAFc his-
tone modifying complex is essential for HOX gene activation and
leukaemic transformation [92].
7. Deregulation of the epigenetic writers
Leukaemic transcription factors acquire novel functions pro-
vided by the fusion partners. For many leukaemic transcription fac-
tors, this gain of function is attributed to the acquisition of
additional epigenetic modiﬁers or writers that modify histone
marks on their target genes.
7.1. Non-SET domain lysine methyltransferase-DOT1L
Among the bewildering number of MLL fusion partners, recent
studies have highlighted some uniﬁed themes regarding their
leukaemogenic mechanism (Fig. 5). The ﬁrst histone modifyingFig. 5. MLL fusions induce transcriptional activation through the recruitment of differ
methyltransferase, DOT1L. Although DOT1L forms a complex with the MLL fusion partner
and AF4/AF5q31 family are not clear. The MLL-EEN fusion interacts with SAM68, PSF and
of target genes. The role of the RNA-binding proteins, PSF and NONO, and their ability oenzyme recruited by MLL fusion partner was reported by Okada
et al. [94]. They demonstrated that DOT1L, a histone methyltrasfer-
ase that speciﬁcally methylates lysine 79 of histone H3, binds to
AF10, a fusion partner of both MLL and CALM [94,95]. Loss-of-func-
tion of DOT1L in cells expressing these leukaemic fusions compro-
mised their oncogenic transformation ability [94–96]. The
involvement of DOT1L in MLL fusion-mediated transformation
was further underscored by the identiﬁcation of its potential asso-
ciation with multiple MLL fusion partners including ENL, AF4/AFF1,
LAF4, AF5q31/AFF4 as well as P-TEFb components, which phos-
phorylates the CTD domain of RNA polymerase II [97,98]. Methyl-
ated H3K79 is associated with transcriptional activation and is
highly enriched in transcribed regions [6,25]. An increased
H3K79 methylation mark was consistently observed in many crit-
ical MLL target genes in both leukaemic cell lines and patient sam-
ples carrying MLL fusions [99–101]. However, co-puriﬁcation
experiments using AF4/AFF1 isolated the AEP complex (AF4/ENL/
P-TEFb) and AF5q31/AFF4 but not DOT1L [102]. Interestingly, an-
other MLL fusion partner, ELL1, recruited elongation complexes
containing AF4/AFF1, AF5q31/AFF4, AF9, ENL and P-TEFb, but not
DOT1L [103]. The discrepancy in the presence or absence of DOT1L
in different MLL fusion complexes implies that there are at least
two distinct types of fusion complexes involving these elongation
factors, i.e., DOT1L or non-DOT1L containing complexes (Fig. 5).
It remains doubtful whether the recruitment of DOT1L is sufﬁcientent epigenetic regulators. MLL fusions differ in their ability to recruit the H3K79
s AF10, AF9 and ENL, its direct interaction and function in MLL fusions involving ELL
NONO. SAM68 serves as an adaptor to link CBP and PRMT1 to activate transcription
f binding to non-coding RNA remain elusive.
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ity of MLL-DOT1L fusion is disputed [94,102]. It is possible that the
recruitment of DOT1L is a direct effect of the MLL fusion protein or
it is just coincidental to the initiation of transcription elongation.
Even though DOT1L and its H3K79 dimethylation marks are pres-
ent at most of MLL fusion target gene loci, its functional role in the
MLL fusion-mediated leukaemogenesis may require further inves-
tigation [99,100].
7.2. Protein arginine methyltransferase (PRMT)
In addition to lysine methylation, recent studies also indicate
that MLL fusions regulate its target gene expression though histone
arginine methylation. Arginine residues are methylated by protein
arginine methyltransferases (PRMTs), where type I and type II
PRMTs catalyse asymmetric and symmetric dimethylation, respec-
tively [104,105]. PRMT-mediated histone arginine methylation is
essential for transcriptional regulation [106]. PRMT1, the major
type I arginine methyltransferase involved in various biochemical
processes, asymmetrically dimethylates its substrates, which har-
bour glycine-arginine rich motifs and arginine 3 of histone 4
(H4R3) and is associated with transcriptional activation
[107,108]. CARM1/PRMT4 is recruited by nuclear receptors to acti-
vate their target genes through histone arginine methylation and/
or by methylation of the splicing complexes [109,110]. Arginine
methylation has been shown to cooperate with other epigenetic
modiﬁcations such as lysine acetylation involved in the transcrip-
tional regulation. Recently, the identiﬁcation of the mutually
exclusive nature of symmetrical dimethylation of H3R2 meditated
by PRMT6, and MLL-mediated H3K4methylation further highlights
the complexity of histone crosstalk involving arginine methylation
[111–113].
The critical role of PRMT function in leukaemogenesis was ﬁrst
reported in the study of the MLL-EEN fusion which transforms hae-
matopoietic progenitor cells and induces leukaemia in vivo [114].
Structure-function analyses demonstrated that SH3 domain of
EEN was the minimal transforming domain, which mediated the
interaction with Prmt1 and three major arginine methylated RNA
binding proteins i.e., SAM68, NONO and PSF [115–117] (Fig. 5).
SAM68, which is also a PRMT1 substrate, belongs to the KH-do-
main containing RNA-binding protein family implicated in RNA
splicing regulation and signal transduction [118]. PSF and NONO
heterodimerise and interact with non-coding RNA (ncRNA) NEAT1
to form the subnuclear ribonucleoprotein body known as para-
speckle [119]. SAM68, which serves as an adaptor to link PRMT1
and CBP for H4R3 arginine methylation and histone acetylation,
respectively, was essential for MLL-EEN-mediated transformation
and target gene expression [114]. Importantly, the direct fusion
of PRMT1, but not the catalytic mutant, to MLL could transform
haematopoietic progenitor cells and therefore strongly supported
the role of PRMT1 in leukaemogenesis [114]. Similar to lysine
methylation, arginine methylation is an reversible process in
which methylated arginine can be antagonised by a deimination
reaction mediated by PADI4, or erased by arginine demethylase
JMJD6 [120,121]. However, their physiological roles in epigenetic
regulation and leukaemogenesis remain poorly understood.
The functional signiﬁcance of the recruitment of PSF and NONO
in MLL-EEN-mediated leukaemogenesis is still unknown. Interest-
ingly, both PSF and NONO have been identiﬁed in oncogenic trans-
locations in renal cell carcinoma whereby their N-terminal RNA
recognition motifs (RRM) were fused with the DNA-binding do-
main of transcription factor, TFE3 [122]. The gain of RNA-binding
activity by these transcription factors may facilitate oncogenesis
by enhancing the coupling of transcription and splicing, or alterna-
tively, enable their interaction with other RNA species for tran-
scriptional or epigenetic regulation. The functional importance ofncRNA in regulating Hox expression and metastasis is highlighted
by a recent discovery of the long intervening ncRNA HOTAIR orig-
inating from the HOXC locus [123–125]. HOTAIR forms a ribonu-
cleoprotein complex with the PRC2 and the LSD1/CoREST/REST
repressor complexes, and represses HOXD gene expression
through epigenetic silencing. However, the role of ncRNA in leu-
kaemogenesis has not been explored and it is unclear whether
the novel RNA-binding activity acquired by oncogenic fusion pro-
teins can facilitate transcriptional activation via RNA-mediated
epigenetic regulator recruitment.
7.3. SET domain containing lysine methyltransferase-NSD family
The nuclear-receptor-binding SET-domain-containing (NSD)
family of proteins (NSD1, NSD2 and NSD3) are histone lysine meth-
yltransferases that harbour the SET domain, PHD and PWWP his-
tone recognition motifs [126,127]. Aberration of NSD1 has been
reported in both AML and in Sotos syndrome, which has predispo-
sition to cancer [128]. NSD1 speciﬁcally trimethylates lysine 36 of
histone H3 and is generally correlated with actively transcribed re-
gions [6]. NSD1 is directly fused with the nucleoporin NUP98 gene
in AML [129]. Retroviral transduction of NUP98-NSD1 transforms
mouse haematopoietic progenitor cells and induces AML in vivo
[126]. The immortalisation activity of this fusion is dependent on
the H3K36 HMT activity of the NSD1 moiety and may mediate
the transcriptional activation of hoxa genes [126]. However, the
status and pathological role of Hox genes in the associated human
disease has not been investigated. In multiple myeloma (MM),
recurrent chromosomal translocations result in the placement of
the multiple myeloma-associated SET (MMSET/WHSC1/NSD2) gene
under the regulation of the IgH enhancer element leading to its
transcriptional dysregulation [130]. Aberrant expression of NSD2
is critical for the oncogenicity of MM cells as its suppression by
gene knockdown and knockout inhibited tumour cell growth
in vitro and reduced tumour formation of MM xenografts [131].
NSD3 is also a fusion partner to NUP98 in AML and is ampliﬁed
in breast cancer cells. Together, these ﬁndings suggest that the gain
of function associated with the NSD SET domain may represent a
common oncogenic mechanism [132,133].
7.4. Lysine acetyltransferase and its crosstalk with PRMTs
Several members of the HAT family are involved in the chromo-
somal translocations in leukaemia patients (Fig. 6). Both CBP and
p300 reciprocally translocate to MLL, which results in an in-frame
fusion containing a large proportion of the CBP/p300 protein [134–
136]. Structure-function analyses using the MLL-CBP fusion identi-
ﬁed both the bromodomain and HAT domain of CBP are required
for transformation of haematopoietic cells [137]. Conditional
MLL-CBP knockin mice develop myeloproliferative disorders and
leukaemia upon c-irradiation or chemical mutagen treatment
[138]. In AML, both CBP and p300 have been shown to be involved
in fusions with MOZ, a member of MYST family HAT protein re-
quired for maintenance of haematopoietic stem cell and hox gene
regulation [139–143]. The chimaeric MOZ fusion protein consists
of the HAT domain of MOZ and the majority of the CBP/p300 pro-
tein. Indirect recruitment of CBP was also reported to be associated
with the MOZ-TIF2 leukaemic fusion whereby MOZ is fused with
the transactivation domains of TIF2 (Transcription intermediary
factor 2) [144,145]. MOZ-TIF2 transformed haematopoietic pro-
genitor cells in vitro and was able to induce AML in vivo. The leu-
kaemogenic activity of the fusion is dependent on both the HAT
activity of MOZ and the recruitment of CBP by the AD1 transactiva-
tion domain of TIF2 [145]. These leukaemic fusion proteins induce
histone hyperacetylation and result in increased Hox gene expres-
sion [145,146] (Fig. 6). Crosstalk of CBP mediated histone acetyla-
Fig. 6. Chromosomal translocations involving histone acetyltransferases (HATs) in human leukaemias. Schematic depiction of MLL and MOZ fusions are shown. These fusions
induce histone hyperacetylation to activate their target genes. PWWP domains of LEDGF and BRPF facilitate the interaction of the fusion proteins with methylated histone.
The potential cross-talk between MLL and MOZ complexes is also illustrated.
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tor-mediated transcription activation, whereby CARM1 and PRMT1
cooperate with CBP in the activation of p53 expression [147]. Inter-
estingly, this mechanism has seemingly been hijacked by the MLL-
EEN leukaemic fusion, which recruits both CBP and PRMT1 to acti-
vate Hox gene expression. Recruitment of HAT is not only limited
to leukaemic fusions. Wild-type MLL protein also recruits MOF
via its C-terminal domain to mediate H4K16 acetylation [148].
Therefore, targeting the activity of different HATs recruited by leu-
kemic fusions or aberrant MLL protein, such as MLL-PTD, may pro-
vide another opportunity for therapeutic intervention.
8. Deregulation of the epigenetic readers
An alternative mechanism contributing to leukaemogenesis is
the misreading of the histone code by leukaemic fusions due to
the aberrant acquisition of a histone reader [149,150]. This is best
illustrated by the leukaemic fusion generated between NUP98 and
H3K4 lysine demethylase JARID1A [151]. The resultant fusion en-
codes the FG repeats of NUP98 and the PHD ﬁnger 3 of JARID1A.
The resultant NUP98-JARID1A lacks the Jmjc enzymatic domain
but shows speciﬁc binding to H3K4me2/me3. The speciﬁc H3K4
binding property of the PHD ﬁnger is required for haematopoietic
transformation mediated by NUP98-JARID1A [150]. PHD of the fu-
sion protein may protect those critical target genes from H3K4
demethylation and gene silencing, which is consistent with the
detection of increased H3K4 methylation and expression of hoxa9
and Meis1 [150]. The transformation ability of NUP98-JARID1A
may also be dependent on CBP and other novel epigenetic mecha-
nisms recruited through the FG repeats of NUP98 to reinforce tran-scription activation as recent studies show chromatin binding of
NUP98 in actively transcribed regions [152,153].
The importance of histone recognition motifs in leukaemogene-
sis is further highlighted by the identiﬁcation of the essential role
of the PWWP motif of Lens-Epithelial Derived Growth Factor
(LEDGF) in MLL-mediated leukaemogenesis [72]. Yokoyama et al.
show that MENIN interacts with the N-terminus of MLL and serves
as an adaptor linking MLL to LEDGF [71,72]. This MENIN–LEDGF
complex is essential for MLL fusion-mediated transformation, as
the loss of either function compromises transformation [71,72].
Detailed mapping of LEDGF has shown that the methyl-lysine
binding PWWP domain is necessary and sufﬁcient to transform
haematopoietic cells when fused directly to a non-transforming
MLL-AF9 deletion mutant that lacks the ability to recruit the ME-
NIN–LEDGF complex [72]. The PWWP domain is a methyl-lysine
recognition motif that is also present in other histone modifying
enzymes and epigenetic regulators [154,155]. Biochemical analy-
ses of the PWWP domain of BRPF1 (Bromodomain and PHD ﬁn-
ger-containing) protein demonstrated speciﬁc binding to the
trimethylated H3K36 mark, which is known to coordinate events
associated with the elongation phase of transcription and is also
emerging as an important epigenetic regulator of pre-mRNA pro-
cessing [154,156]. Interestingly, BRPF1, which is required for Hox
regulation during development, was also identiﬁed to complex
with MOZ [157–159]. In addition to the methyl-lysine binding mo-
tif, the bromodomain is also necessary for MLL-CBP mediated leu-
kaemogenesis [137]. Thus, understanding how different leukaemic
transcription factors read the histone marks on target genes with
their speciﬁc histone recognition motifs may create new opportu-
nities for therapeutic targeting.
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The intricate mechanisms utilised by the different leukaemic
fusions in the activation of their target genes underscores the
importance of epigenetic regulation during carcinogenesis. Pertur-
bation of the epigenetic network by the acquisition of somatic
mutations in some critical histone modifying enzymes can result
in the global gene deregulation of multiple signalling pathways
that may facilitate clonal evolution of malignant cells. In this sec-
tion, the mutations affecting the physiological function of the epi-
genetic regulators will be discussed.
8.1.1. Epigenetic regulators of H3K27 methylation: EZH2 and UTX
Enzymes regulating H3K27 methylation are frequently mutated
in haematological malignancies. Somatic mutation of the histone
methyltransferase, EZH2, was ﬁrst detected in follicular and diffuse
large B-cell lymphomas of germinal-centre origin [160]. This muta-
tion involves a speciﬁc replacement of tyrosine 641 by histidine at
the catalytic SET domain that results in the reduced H3K27 meth-
yltransferase activity in vitro [160]. Similarly, EZH2 inactivation
mutations were also independently identiﬁed in MDS, a heteroge-
neous group of acquired haematological disorders characterised by
dysplasia of the myeloid, erythroid and megakaryocytic lineages
[161–163]. While the pathological signiﬁcance and underlying
transformation mechanism of EZH2 mutation is still largely un-
known at this stage, the loss or reduced PRC2 activity due to
EZH2 mutation could potentially disturb the dynamics of epige-
netic regulation, in particular, for those engaged in the bivalent
chromatin state. Gene expression proﬁling of leukaemic cells and
other human malignancies reveals the similarity of their transcrip-
tion proﬁles to embryonic stem cells [164,165]. The majority of
bivalent genes lose the active H3K4me3 mark and get silenced
by the PRC2-mediated H3K27 methylation after lineage commit-
ment and haematopoietic differentiation [29]. Therefore, defective
EZH2 silencing may facilitate the oncogenic transformation of cells
by inadvertently allowing the aberrant transcriptional activation of
genes involved in self-renewal and blocking haematopoietic differ-
entiation. Alternatively, it is also possible that loss of an antagonis-
tic epigenetic repressor may reduce the epigenetic threshold and
facilitate the activation of some critical target genes by oncogenic
stimuli, thus making cells harbouring those epigenetic defects
more susceptible to transformation.
The genetic data linking EZH2 mutation to haematological
malignancy is in stark contrast to those reported in solid tumours
[166]. EZH2 is overexpressed in breast and prostate cancer and its
overexpression is associated with metastatic progression in pros-
tate cancer [167,168]. Overexpression of EZH2 may augment
PRC2-mediated gene silencing and cause obligate transcriptional
repression. Obligate gene silencing could also be contributed by
the inactivation mutation of an antagonistic H3K27 demethylase,
such as UTX, whereby a loss-of-function mutation has been identi-
ﬁed in some human myeloma cell lines [169]. Reduced or loss of
H3K27 demethylase activity or hyperactive PRC2 activity may lead
to the obligate silencing of tumour surveillance genes such as tu-
mour suppressor genes. Deregulation of tumour suppressor genes
at the INK4A-ARF loci is highly plausible with studies showing that
the H3K27 methylation status of INK4A-ARF loci are regulated by
the interplay of PRC2 complex and H3K27 demethylase JMJD3
[170–172].
8.1.2. Asxl1
Mutations of Additional Sex Combs-Like 1 (ASXL1), a gene re-
lated to the polycomb family, were reported in MDS, AML and
CML [173–176]. ASXL1, a mammalian homolog of Drosophila addi-
tional sex combs, is involved in embryonic development and is re-
quired for both the activation and repression of Hox genes [177].Asxl1 mutant mice mis-express Hox genes resulting in defective
haematopoiesis with variable defect in the lymphoid and myeloid
compartments [178]. Interestingly, Asxl1 knockout mice did not
develop haematological malignancy, suggesting that ASXL1 muta-
tion may not be sufﬁcient for leukaemia induction [178]. However
it is also noted that mutation in Asxl1 knockout mice is slightly dif-
ferent from the human ASXL1 mutation, which clusters predomi-
nately within exon 12 and results in the expression of a
truncated protein lacking only the C-terminal PHD ﬁnger with a
possible dominant negative effect on the wild-type or other related
proteins [173,174,178]. Recently, a polycomb repressive complex,
PR-DUB, was identiﬁed to contain ASXL1 and the histone deubiqu-
itinase BAP1, which removes monoubiquitin from H2A, but not
from H2B [179]. Therefore, it is also tempting to speculate that
the mutant ASXL1 may affect the activity, formation or targeting
of PR-DUB complexes leading to the perturbation of H2A ubiquiti-
nation dynamics and the deregulation of critical PRC target genes
such as Hox.
8.1.3. TET family
The TET family proteins include three members, TET1, TET2 and
TET3, which share a conserved cysteine-rich region and the dioxy-
genase motif involved in Fe(II) and a-ketoglutarate binding. Recent
studies have shown that TET1 enzymatically converts 5-methyl-
cytosine (5mC) to 5-hydroxylmethylcytosine (5-hmC) [180]. Loss
of Tet1 function resulted in increased promoter DNA methylation,
suppression of Nanog expression and induced ESC differentiation
[181]. TET1 is a translocation partner of MLL in AML [182,183],
whereas TET2 is mutated in patients with MDS and other myeloid
malignancies [184–191]. TET2 loss-of-function mutations in mye-
loid malignant cells resulted in uniformly low levels of 5hmC
and, surprisingly, hypomethylation instead of hypermethylation
of genomic DNA and the majority of the differentially methylated
CpG sites compared to bone marrow samples from healthy con-
trols [192]. Thus while it is plausible that deregulation of TET pro-
teins may result in perturbation of global DNA methylation leading
to transcriptional deregulation of critical target genes for leukae-
mogenesis, the actual functional consequence of TET mutation
and 5hmC in gene expression is still unclear.
8.1.4. Jak2
Gain-of-function mutations of Janus kinase 2 (JAK2) leads to
constitutive tyrosine kinase activity and is frequently detected in
myeloid malignancies [193]. JAK2 phosphorylates and activates
the transcription factor, signal transducer and activator of tran-
scription 5 (STAT5), a major substrate for JAK2, to mediate its bio-
logical response [193]. The role of JAK2 in epigenetic regulation
was elusive until Dawson et al. showed that nuclear JAK2 phos-
phorylates tyrosine 41 of histone H3 that resulted in the release
of the transcription repressor, heterochromatin protein 1 a
(HP1a), from chromatin. The exclusion of HP1a results in the tran-
scription of genes normally repressed by HP1a, such as LMO2
[194]. JAK2 has also been reported to collaborate with JMJD2C to
activate gene expression critical for lymphoma survival [195]. Gi-
ven the prevalence of kinase deregulation in human cancer, it will
be interesting to investigate the potential nuclear function of other
kinases and their roles in the epigenetic regulation of transcription.
8.2. Prospective
Although our knowledge on the genetics aspect of leukaemo-
genesis has been improved signiﬁcantly in the last few decades,
the epigenetic mechanisms utilised by various leukaemic fusion
proteins are yet to be explored. In addition to the epigenetic writ-
ers and epigenetic readers described in some detail above, the
landmark discovery of histone demethylases (epigenetic erasers)
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ties for further scientiﬁc pursuit. Identiﬁcation of speciﬁc mutation
of epigenetic regulators and the altered epigenomes in leukaemias
pave the way for extended screening and identiﬁcation of putative
therapeutic targets with the use of the synthetic lethality approach
[196–198]. In the near future, a better understanding of the gain or
loss-of-function of those oncogenic transcription factors and epige-
netic modifying enzymes essential for pre-leukemic or leukemic
stem cells will provide important insights into the identiﬁcation
of amenable targets for therapeutic intervention [199].
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